Tear flow in cyclosporine recipients

Area of Science:

• Ophthalmology
• Nephrology
• Immunology

Background:

• Kidney transplant recipients often experience ocular complications, including dry eye.
• Immunosuppressive therapies, such as cyclosporine and azathioprine, are crucial for graft survival.
• The impact of these medications on tear production is not fully understood.

Purpose of the Study:

• To evaluate the effect of oral cyclosporine on tear flow in renal allograft recipients.
• To compare tear flow in patients receiving cyclosporine versus azathioprine and control groups.

Main Methods:

• A Schirmer test was performed on control subjects, dialysis patients, and kidney transplant recipients on cyclosporine or azathioprine.
• Tear flow was measured over 4 minutes using a standardized test with topical anesthetic.
• Data analysis included comparisons between and within groups.

Main Results:

• Kidney transplant recipients on cyclosporine demonstrated significantly increased tear flow (19.0 mm/4 minutes) compared to controls (10.6 mm/4 minutes), dialysis patients (13.6 mm/4 minutes), and azathioprine recipients (10.4 mm/4 minutes).
• Tear flow in control subjects, dialysis patients, and azathioprine recipients was statistically similar.
• No significant differences in tear flow were observed based on sex or race within groups.

Conclusions:

• Oral cyclosporine significantly enhances tear flow in kidney transplant recipients, independent of autoimmune lacrimal disease.
• Azathioprine and medications used by dialysis patients did not significantly alter tear flow compared to controls.
• Cyclosporine's effect on tear production warrants further investigation in the context of post-transplant ocular health.